"Sanofi-Aventis (SNY), a pharmaceutical products company, is a buy based on our 'Benjamin Graham value' model," says John Reese who assesses stocks based on the investment criteria of numerous "legendary" investors.

The editor of Validea, explains, "Indeed, the stock earns a 100% score, meeting all of the investment criteria we review in for this value-oriented screen.

Although short-term news may seem bright for Eli Lilly & Co. (LLY), the broader picture for the company looks flat. Having dropped from an average share price in the $53 range over two years ago, to a current average share value hovering near $35, investors are signaling that the long range forecast for Lilly is unexciting at best.

It appears that Lilly shall be buoyed in the near term by the recent FDA approval of testosterone replacement therapy Axiron for sale in the U.S. Lilly purchased rights to Axiron from Australian firm, Acrux for an initial payment of $50 million plus $3 million based on the transfer of manufacturing assets.

Today was another up day, mostly thanks to the new Basel III banking accords showing that most banks are actually not in need of fresh capital any time in the immediate future. We also saw Warren Buffett refute that there is a double-dip recession and we also had a slightly less-atrocious August Treasury deficit than expected. This was a day where traders began putting back on the risk trade.

Here were today's closing bell levels:

DJIA
S&P500
NASDAQ

Analyst Upgrades

• BMO Capital upgraded Noble Energy (NE) to outperform from market perform and raised its target to $85 from $78. The firm upgraded Noble based on Niobrara field potential and record-breaking reserve potential at the Leviathan prospect.
• Wells Fargo upgraded Raytheon (RTN) to outperform from market perform based on relative valuation, strong balance sheet and International sales exposure.
• ThinkEquity upgraded Cerner (CERN) to buy from hold based on valuation and EMR momentum. The firm raised its price target on shares to $86 from $80.
• Sanofi-Aventis (SNY) was upgraded to buy from hold at Societe Generale.
• Cavium Networks (CAVM) was upgraded to outperform from market perform at JMP Securities.
• CSG Systems (CSGS) was upgraded to outperform from perform at Oppenheimer.

Analyst Upgrades

• JPMorgan upgraded Coca-Cola (KO) to overweight from neutral due to valuation and expectations that developed market volume should improve. The firm raised its target price for shares to $66.
• BB&T upgraded Nordson (NDSN) to buy from hold and has an $82 price target on the stock. The firm believes certain drivers of Nordson's Advanced Tech unit are becoming more secular vs. cyclical and that the company's EBIT margins can go higher.
• Credit Suisse upgraded Embraer (ERJ) to outperform from underperform, citing the positive announcements from the Famborough Air Show. The firm raised its price target to $37 from $21.
• Universal Health (UHS) was upgraded to outperform from sector perform at RBC Capital.
• Mead Johnson (MJN) was upgraded to conviction buy from buy at Goldman.
• Coventry Health (CVH) was upgraded to outperform from market perform at Leerink.

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.